Barclays analyst Andrew Mok lowered the firm’s price target on Astrana Health (ASTH) to $26 from $36 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s contracting trade-off is understandable, but introduces an element of risk to its EBITDA targets in 2026 and 2027, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health price target lowered to $35 from $40 at TD Cowen
- Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth
- Astrana Health Reports Strong Revenue Growth in Q3 2025
- Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health
- Astrana Health Reports Strong Q3 Revenue Growth